Login
$EQ
$1.36 +$0.11 (8.8%) Close

Company Executives

$EQ Management Team

Mr. Daniel Bradbury

Executive Chairman of the Board

Age 64
Compensation $190.0K USD
Sex Male

Mr. Bruce Steel

President

Chief Executive Officer

Director

Age 58
Compensation $684.4K USD
Sex Male

Dr. Stephen Connelly

President

Chief Scientific Officer

Age 43
Compensation $519.4K USD
Sex Male

Ms. Christine Zedelmayer

Chief Operating Officer

Age 55
Compensation $506.2K USD
Sex Female
Directors
7
serving now
Independent
4 of 7
stated in the proxy
Average tenure
7.7 years
from year joined
CEO also chairs the board
No
Daniel M. Bradbury
Director Age On board Independent Committees Other public boards 2025 pay Source
Charles McDermott
54 2018
8 years
Independent None stated None stated $61,462
Bruce D. Steel
59 2017
9 years
Not independent None stated None stated Paid as CEO
Daniel M. Bradbury
64 2017
9 years
Not independent None stated Castle Biosciences, Inc, Biocon Biologics Ltd., Vivani Medical, Inc. $177,289
Martha J. Demski
73 2018
8 years
Independent None stated Alpha Teknova Inc. $76,462
Mark Pruzanski
58 2018
8 years
Independent None stated None stated $63,337
Barbara Troupin
58 2022
4 years
Independent
Audit Committee Nominating and Corporate Governance Committee
None stated $63,962
Peter Colabuono
Not stated Not stated Not independent None stated None stated $48,962

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 15, 2026
Biocon Limited
former holder of more than 5% of our common stock
$363,000
2025

Termination agreement ending the Biocon Agreements; technical service fee owed to us set off against amounts we owed Biocon

With Equillium Open in proxy
Biocon Limited
$0.4 million
2024

Co-funding of a Phase 2 clinical study of itolizumab in ulcerative colitis conducted by Biocon in India; our share of study costs

With Equillium Open in proxy
Syngene International Limited
wholly-owned subsidiary of Biocon
$5.4 million
July 2023

Work order with Syngene for chemistry, manufacturing and controls services for itolizumab, substantially all paused in Q3 2024

Decheng Capital Management III (Cayman) LLC
beneficial owner of more than 5% of our common stock
$0.5 million

Acquisition of Ariagen under a stock purchase agreement; we assumed Ariagen liabilities and may owe regulatory approval milestones, up to $50.6 million of which would go to Decheng affiliates

With Ariagen Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support